Clinical Trial Update: A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating rucaparib in pancreatic cancer patients with a deleterious BRCA mutation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Rucaparib (rucaparib)

Snippet

Sponsor: pharmaand GmbH | Conditions: Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma | Phase 2 | Status: COMPLETED